# Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

> **NCT01490060** · NA · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Sarcoma
- Chemotherapy-induced Nausea and Vomiting
- Effects of Chemotherapy
- Adverse Effects of Medical Drugs

## Interventions

- **DRUG:** Fosaprepitant
- **DRUG:** Dexamethasone
- **DRUG:** 5HT3 receptor antagonist
- **DRUG:** Ifosfamide-based chemotherapy (AI)
- **DRUG:** Doxorubicin
- **DRUG:** Mesna
- **DRUG:** Ifosfamide
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT01490060
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490060, "Fosaprepitant in Patients Receiving Ifosfamide-based Regimen". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01490060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*